Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (NASDAQ: SRTS).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Sensus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here […]

Pomerantz LLP is investigating claims on behalf of investors of CPI Card Group Inc. (“CPI” or the “Company”) (NASDAQ: PMTS).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether CPI and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click

Pomerantz LLP is investigating claims on behalf of investors ofSpirit Aviation Holdings, Inc.(“Spirit” or the “Company”)(NYSE: FLYY). Such investors are advised to contact DaniellePeyton atnewaction@pomlaw.comor 646-581-9980, ext. 7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Spirit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information

Pomerantz LLP announces that a class action lawsuit has been filed against SelectQuote, Inc. (“SelectQuote” or the “Company”)(NYSE: SLQT). Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg

Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S(“Novo Nordisk” or the “Company”)(NYSE: NVO). Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Pomerantz LLP announces that a class action lawsuit has been filed against Sable Offshore Corp. (“Sable” or the “Company”) (NYSE: SOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of

Pomerantz LLP is investigating claims on behalf of investors of Luminar Technologies, Inc. (“Luminar” or the “Company”) (NASDAQ: LAZR).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Luminar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here

PomerantzLLP is investigating claims on behalf of investors of Galiano Gold Inc. (“Galiano” or the “Company”) (NYSE: GAU).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Galiano and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for

Pomerantz LLP is investigating claims on behalf of investors of The Hain Celestial Group, Inc. (“Hain” or the “Company”) (NASDAQ: HAIN).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Hain and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Pomerantz LLP is investigating claims on behalf of investors of aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether aTyr and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here